Pasar al contenido principal

IDENTIFICACION DE RUTAS INMUNOLOGICAS Y NEUROENDOCRINAS REGULADAS POR BACTERIAS INTESTINALES QUE AYUDEN A COMBATIR LA OBESIDAD

PID2020-119536RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 22
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Effect and Mechanisms of Action of Intestinal Bacteria and Bioactive Compounds on the Immune System and Metabolism in Obesity Models

  • Liébana García, Rebeca
[ES] La obesidad representa un importante reto para la salud pública debido a su elevada prevalencia y a las comorbilidades asociadas. Las dietas hipercalóricas activan el sistema inmunitario intestinal y alteran la microbiota intestinal causando daños metabólicos en el organismo. De hecho, la pérdida de homeostasis inmunológica intestinal se considera un evento que precede a la aparición de la inflamación sistémica de bajo grado asociada a la obesidad. Dado que la microbiota intestinal es un factor modificable, su modulación puede convertirse en una oportunidad para reducir el impacto de la obesidad. Por ello la identificación de los factores que participan en la respuesta inflamatoria a las dietas obesogénicas y la búsqueda de alternativas terapéuticas basadas en la microbiota constituyen una vía de investigación prometedora para combatir la obesidad. Esta Tesis Doctoral evalúa el potencial de nuevos probióticos y estrategias dietéticas para combatir la obesidad basadas en sus propiedades inmunomoduladoras. En el Primer Capítulo investigamos el potencial anti-obesogénico del propil propano tiosulfinato (PTS), un compuesto organosulfurado derivado de la especie Allium, en dos dosis diferentes (0,1 o 1 mg/kg/día) utilizando un modelo murino de obesidad inducida por la dieta (DIO). Nuestros hallazgos demostraron los efectos protectores de PTS frente a la obesidad, ya que su administración redujo el peso corporal y mejoró la homeostasis de glucosa. En el tejido adiposo y el hígado, PTS redujo la inflamación y el metabolismo lipídico aberrante causado por la dieta obesogénica. Además, PTS incrementó la actividad termogénica en el tejido adiposo marrón y reforzó la función barrera intestinal. En vista de los modestos cambios en el ecosistema microbiano intestinal, concluimos que estos efectos no eran mediados por la microbiota. En el Segundo Capítulo evaluamos el potencial anti-obesogénico y el mecanismo de acción de una nueva bacteria llamada Phascolarctobacterium faecium DSM 32890. Para ello, realizamos diferentes experimentos in vitro e in vivo usando diferentes cultivos celulares (macrófagos derivados de médula ósea y células linfoides innatas intestinales del grupo 1 (LC1s)) y modelos murinos DIO (ratones C57BL/6J y Rag1-/-). El tratamiento de ratones alimentados con una dieta hipercalórica con P. faecium incrementó la proporción de los macrófagos M2 en el intestino, lo que contrarrestó el aumento de ILC1s y, en última instancia, mitigó la intolerancia a la glucosa y el aumento de peso corporal, independientemente de la viabilidad de la bacteria. Además, P. faecium reforzó la función barrera intestinal y evitó la inflamación sistémica causada por la dieta hipercalórica. Estos beneficios metabólicos se mantuvieron en ausencia de inmunidad adaptativa, pero se perdieron cuando la bacteria se coadministró con un inhibidor (GW2580) de la polarización de macrófagos M2. Por último, realizamos un amplio estudio con datos metagenómicos de 6.361 personas que mostró una relación inversa entre P. faecium y la obesidad, independientemente de la nacionalidad, el sexo o la edad, lo que sugiere la asociación de esta bacteria con la salud metabólica. En el Tercer Capítulo, investigamos la implicación de las ILC1s intestinales en la progresión de la obesidad y las alteraciones metabólicas asociadas. Para ello, evaluamos longitudinalmente la respuesta de las ILC1s y las consecuencias su depleción de ILC1s en un modelo murino DIO. En el intestino, el bloqueo de ILC1s evitó el aumento de macrófagos M1 e ILC2s y promovió la activación de la vía ILC3-IL22, aumentando la producción de mucina, la expresión de péptidos antimicrobianos y el número de células neuroendocrinas. Además, el bloqueo de ILC1s restableció el perfil microbiano y el metaboloma, acercándose al perfil asociado con la salud metabólica. En última instancia, estas mejoras se asociaron con una mayor secreción de hormonas intestinales, y una reducción de la insulinemia y la adiposidad., [CA] L'obesitat és un repte per a la salut pública degut a la elevada prevalença i les comorbiditats. Les dietes hipercalòriques activen el sistema immunitari intestinal i alteren la microbiota intestinal causant danys metabòlics en l'organisme. De fet, la pèrdua d'homeòstasi immunològica a escala intestinal es considera un esdeveniment primerenc que precedeix l'aparició de la inflamació sistèmica de baix grau associada a l'obesitat. Atés que la microbiota intestinal és un factor modificable, la seua modulació pot convertir-se en una oportunitat per a reduir l'impacte de l'obesitat. Per això, la identificació dels factors que participen en la resposta inflamatòria a les dietes obesogèniques i la recerca d'alternatives terapèutiques basades en la microbiota son una via d'investigació prometedora per a combatre l'obesitat. Aquesta Tesi Doctoral avalua el potencial de nous probiòtics i estratègies dietètiques per a combatre l'obesitat basada en propietats immunomoduladores. En el Primer Capítol investiguem el potencial anti-obesogènic del propil propà tiosulfat (PTS), un compost organosulfurat derivat de l'espècie Allium, en dues dosis diferents (0,1 o 1 mg/kg/dia) utilitzant un model murí d'obesitat induïda per la dieta. Els resultats demostren els efectes protectors de PTS enfront a l'obesitat, ja que la seua administració va reduir el pes corporal i va millorar l'homeòstasi de glucosa. En el teixit adipós i el fetge, PTS va prevenir l'augment de la resposta inflamatòria i les alteracions del metabolisme lipídic causades per la dieta hipercalòrica. A més, PTS va incrementar l'activitat termogènica en el teixit adipós marró i millorà la funció barrera intestinal alterats per la dieta. Observàrem canvis modestos en la microbiota intestinal, concloent que els efectes no estan mediats de manera significativa per la microbiota. En el Segon Capítol avaluem el potencial anti-obesogènic i el mecanisme d'acció d'un nou bacteri Phascolarctobacterium faecium DSM 32890. Hem realitzat experiments in vitro i in vivo utilitzant diferents cultius cel·lulars (macròfags derivats de medul·la òssia i de cèl·lules limfoides innates intestinals del grup 1 (LC1s) i models murins d'obesitat induïda per la dieta (ratolins C57BL/6J, i Rag1-/- ). El tractament de ratolins alimentats amb una dieta hipercalòrica amb P. faecium incrementà la proporció dels macròfags M2 a l'intestí, contrarestant l'augment d'ILC1s i en última instància, mitigà la intolerància a la glucosa i l'augment del pes corporal, independentment de la viabilitat del bacteri. A més, P. faecium reforçà la funció bacterial intestinal i evità la inflamació sistèmica causada per la dieta hipercalòrica. Aquests beneficis metabòlics es mantenien en absència d'immunitat adaptativa, però es perderen quan el bacteri es coadministrà amb un inhibidor (GW2580) de la polarització de macròfags M2. Finalment, realitzàrem un ampli estudi amb dades metagenòmiques de 6.361 persones que mostrà una relació inversa entre P. faecium i l'obesitat, independentment de la nacionalitat, el sexe o l'edat, suggerint l'associació d'aquest bacteri amb la salut metabòlica. En el Tercer Capítol, investiguem la implicació de les ILC1s residents en l'intestí en la progressió de l'obesitat i les alteracions metabòliques associades. Evaluàrem longitudinalment la resposta de les ILC1s i les conseqüències de la depleció de ILC1s en un model murí d'obesitat. A l'intestí, el bloqueig de ILC1s va evitar l'augment de macròfags M1 i ILC2s, i va promoure l'activació de la via ILC3-IL22, augmentant la producció de mucina, l'expressió de pèptids antimicrobians i el nombre de cèl·lules neuroendocrines. El bloqueig de ILC1s va restablir la microbiota i el seu metaboloma, similar a l'estat saludable. Aquestes millores es van associar amb una major secreció d'hormones intestinals, i una reducció de la insulinèmia i l'adipositat., [EN] Obesity is a major public health challenge due to its high prevalence, and association with metabolic comorbidities. Hypercaloric diets are known to overactivate the intestinal immune system and disrupt the microbiome, ultimately causing detrimental metabolic effects. The loss of intestinal immune homeostasis is considered an early step preceding the development of systemic low-grade inflammation associated with obesity and metabolic complications. In this regard, extensive evidence supports that the gut microbiome may be modified favorable and, thus, help to ameliorate these conditions. Hence, identifying factors triggering the low-grade inflammation and microbiome-base solutions to reduce the obesity burden represent promising avenues of research. This Doctoral Thesis aims to advance the knowledge and provide novel probiotics and dietary strategies to combat the burden of obesity based on their immunomodulatory properties to shape the metabolic response to the diet. In the First Chapter, we have investigated the anti-obesogenic potential of propyl propane thiosulfinate (PTS), an organo-sulfur compound derived from Allium species, at two different doses (0.1 or 1 mg/kg/day) using a murine model of diet-induced obesity (DIO). Our preclinical findings showed the protective effects of PTS against obesity, reducing body weight gain and maintaining glucose homeostasis, thus suggesting its potential to ameliorate the impact of the HFHSD. In the adipose tissue and the liver, PTS reduced inflammation and the aberrant lipid metabolism caused by the obesogenic diet. Additionally, PTS promoted thermogenic activity in the brown adipose tissue and enhance intestinal gut barrier defense. In view of the modest changes in the microbial ecosystem, we concluded that the effects of PTS were not mediated by the gut microbiota. In the Second Chapter, we have evaluated the anti-obesogenic potential and the mechanism of action of the new intestinal strain, Phascolarctobacterium faecium DSM 32890, isolated in our laboratory from a healthy volunteer. To that aim, we have performed different in vitro and in vivo experiments, including the use of different types of cell cultures (bone marrow-derived macrophages and group 1 of innate lymphoid cells (ILC1s)) and DIO murine models (wild-type C57BL/6J and Rag1-/- mice). Treatment of HFHSD-fed mice with P. faecium, regardless of its viability, shifted the macrophage phenotype towards an M2-type, which counteracted the obesity-induced increase in gut-resident ILC1s and ultimately mitigated glucose intolerance and body weight gain. Moreover, P. faecium treatment prevented systemic inflammation, boosted secretory immunoglobulin A production and induced antimicrobial peptide and interleukin 22 expression. These metabolic benefits were maintained in the absence of an adaptive immune system but were lost when the bacterium was co-administered with an inhibitor (GW2580) of M2 macrophage polarization. We confirmed that P. faecium was more prevalent in the gut metagenomes of non-obese adults regardless of nationality, sex or age, suggesting that it might contribute to safeguard metabolic health in humans. In the Third Chapter, we have investigated the involvement of gut-resident ILC1s in obesity progression and metabolic disruption. To address this goal, we evaluated longitudinally, in a DIO murine model, the ILC1s response to an obesogenic diet and the consequences of the ILC1s depletion. In the intestine, ILC1s depletion blunted the increases in M1 macrophages and ILC2s. Additionally, ILC1s depletion promoted the ILC3-IL22 pathway, increasing mucin production, the expression of antimicrobial gut peptides, and the number of neuroendocrine cells. Moreover, ILC1s depletion restored microbial and metabolomic profiles, resembling those associated with a healthy symbiotic state. The improvements in gut homeostasis were linked to a higher gut hormone secretion, and reduced insulinemia and adiposity., Rebeca Liébana García has been beneficiary of an FPU contract (FPU 18/02026) and a mobility grant (EST22/00430) from Spanish Ministry of Universities. The experimental work conduced in this Doctoral Thesis has been funded by the Spanish Ministry of Science and Innovation (MICINN AGL2017-88801-P, PID2020-119536RB-I00), the Centre for the Development of Industrial Technology (CDTI, Ref 20170847), and the EU H2020 Marie Sklodowska Curie Actions (MSCA-IF “MicroILCs, GA: 8905454).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

The Ablation of Sensory Neurons Expressing the Nav1.8 Sodium Channel Improves Glucose Homeostasis and Amplifies the GLP-1 Signaling in Obese Female Mice

  • Romaní-Pérez, Marina
  • Bullich-Vilarrubias, Clara
  • López-Almela, Inmaculada
  • Sanz, Yolanda
[EN] Scope Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females. Methods and results Mice lacking neurons expressing the sodium channel Nav1.8 were generated using an ablation strategy based on cre recombinase-mediated expression of diphtheria toxin fragment A (DTA) (Nav1.8-cre/DTA mice) to investigate whether these neurons modulate body weight, food intake, gut hormone secretion, gastrointestinal transit, and glucose tolerance in response to nutrient challenges in a sex-dependent manner. Male Nav1.8-cre/DTA mice show resistance to gain weight in response to high-fat high-sugar diet (HFHSD), whereas females lacking Nav1.8+ neurons have improved oral glucose tolerance accompanied by higher insulin levels and attenuated glucagon secretion after an oral glucose load. Female Nav1.8-cre/DTA mice also show higher fasting and postprandial glucagon like peptide-1 (GLP-1) levels with an increased number of GLP-1-positive cells. Finally, ablation of Nav1.8-expressing neurons accelerates the gastrointestinal transit in female mice under HFHSD. Conclusion This data demonstrates sex-dependent differences in the Nav1.8-mediated regulation of energy metabolism, and provides new insights that may help in the design of sex-specific neuromodulation therapies for metabolic disorders induced by diets rich in fats and simple sugars., The authors thank Inmaculada Noguera for excellent technical assistance and the animal technicians for animal care (SCSIE, University of Valencia), and to Dr. Jose Maria Coll Marques (IATA-CSIC) for support in imaging procedures. This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (M.R.P.), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission - NextGenerationEU, through the "CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+" (PTI-NEURO-AGING+). The grant of the Spanish Ministry of Science and Innovation (MCIN/AEI) to IATA-CSIC as Accredited Center of Excellence (CEX2021-001189-S/ MCIN/AEI/10.13039/501100011033) is acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Tesis doctoral (DoctoralThesis)

Influence of gut-to-brain neuroendocrine pathways and intestinal microbiota on energy homeostasis

  • Bullich Vilarrubias, Clara
[ES] La obesidad es un gran reto de salud pública que ha alcanzado proporciones epidémicas. El entorno "occidentalizado" en el que vivimos, caracterizado por la accesibilidad a alimentos hipercalóricos, contribuye al desequilibrio crónico entre energía ingerida y gasto energético que causan la obesidad. Las intervenciones conductuales diseñadas para la pérdida de peso tienen limitada efectividad a largo plazo, por lo que existe una urgente necesidad de desarrollar estrategias más eficaces y seguras para prevenir y tratar la obesidad y sus comorbilidades. El desarrollo de estrategias terapéuticas dirigidas al intestino para mejorar la salud metabólica requiere un conocimiento en profundidad de las vías de señalización neuroendocrina intestinal que regulan el la ingesta y el equilibrio energético. El objetivo de esta tesis ha sido profundizar en las interacciones intestino-cerebro implicadas en el control de la homeostasis energética, incluyendo los componentes endocrinos, neurales y la microbiota intestinal, en el contexto del desarrollo de la obesidad inducida por una dieta hipercalórica. En los Capítulos 1 y 2 hemos explorado nuevas funciones de las neuronas sensoriales aferentes que expresan el canal de sodio Nav1.8 en el control de la homeostasis energética, considerando las diferencias entre sexos. Hemos generado un modelo de ratón carente de las neuronas Nav1.8+ mediante ablación con toxina diftérica. En el Capítulo 1 hemos demostrado que las neuronas Nav1.8+ son indispensables para regular específicamente según el sexo las vías neurales y endocrinas implicadas en la homeostasis energética. En hembras, la ablación de estas neuronas mejora la regulación de la glucosa postprandial potenciando la señalización enteroendocrina de GLP-1 y acelera el tránsito intestinal, mientras que en machos induce resistencia al aumento de peso inducido por una dieta obesogénica. En el Capítulo 2 hemos demostrado que, en machos, la ablación de las neuronas Nav1.8+ altera el control coordinado de la ingesta i las variaciones de peso diarias, además de alterar la señalización enteroendocrina y las oscilaciones diarias de la microbiota intestinal en respuesta al estado nutricional (ayuno/ingesta), y perturbar la homeostasis del sistema inmune intestinal. En el capítulo 3, hemos usado un modelo de ratón con obesidad inducida por dieta para explorar los mecanismos por los cuales Phascolarctobacterium faecium DSM 32890, una cepa bacteriana intestinal aislada de humanos metabólicamente sanos, previene la obesidad modulando la ingesta. La administración de P. faecium reduce la ingesta calórica gracias a la hipersecreción de la hormona gastrointestinal saciante el PYY. Independientemente de sus efectos anorexigénicos, la bacteria ejerce sus beneficios metabólicos estimulando el tránsito intestinal y reduciendo la absorción intestinal de lípidos, evitando la acumulación de grasa corporal. En conclusión, esta tesis doctoral proporciona evidencia preclínica que contribuye a una comprensión más precisa de las vías neuroendocrinas que comunican el intestino y el cerebro, y del papel que tiene la microbiota intestinal en la regulación de la ingesta y el gasto energético. Destacamos la importancia de las neuronas sensoriales aferentes Nav1.8+ en la detección de estímulos intestinales por quimiorreceptores para regular el balance energético en ambos sexos, lo cual abre una nueva línea de investigación para diseñar herramientas de neuromodulación de las neuronas Nav1.8+ con el fin de prevenir y tratar los trastornos metabólicos inducidos por la dieta, de forma específica para cada sexo. También destacamos que P. faecium es una bacteria candidata como probiótico de nueva generación, ya que modula el sistema enteroendocrino del hospedador y previene la obesidad en un modelo preclínico. En conjunto, estos hallazgos proporcionan una base para el desarrollo de estrategias terapéuticas basadas en el intestino dirigidas a combatir la obesidad y comorbilidades asociadas., [CA] L'obesitat és un gran repte de salut pública que ha assolit proporcions epidèmiques. L'entorn "occidentalitzat" en el que vivim, caracteritzat per l'accessibilitat a aliments hipercalòrics, contribueix al desequilibri crònic entre energia ingerida i despesa energètica que causen l'obesitat. Les intervencions conductuals dissenyades per a la pèrdua de pes tenen una eficàcia limitada a llarg termini, per la qual cosa hi ha una necessitat urgent de desenvolupar estratègies més eficaces i segures per a prevenir i tractar l'obesitat i les seues comorbiditats. El desenvolupament d'estratègies terapèutiques dirigides a l'intestí per a millorar la salut metabòlica requereix un coneixement en profunditat de les vies de senyalització neuroendocrina intestinal que regulen la ingesta i l'equilibri energètic. L'objectiu d'aquesta tesi ha sigut aprofundir en les interaccions intestí-cervell implicades en el control de l'homeòstasi energètica, incloent els components endocrins, neurals i la microbiota intestinal, en el context del desenvolupament de l'obesitat induïda per una dieta hipercalòrica. En els Capítols 1 i 2 hem explorat noves funcions de les neurones sensorials aferents que expressen el canal de sodi Nav1.8 en el control de l'homeòstasi energètica, considerant les diferències entre sexes. Hem generat un model de ratolí mancat de les neurones Nav1.8+ mitjançant ablació amb toxina diftèrica. En el Capítol 1 hem demostrat que les neurones Nav1.8+ són indispensables per a regular, específicament segons el sexe, les vies neurals i endocrines implicades en l'homeòstasi energètica. En femelles, l'ablació d'aquestes neurones millora la regulació de la glucosa postprandial potenciant la senyalització enteroendocrina de GLP-1 i accelera el trànsit intestinal, mentre que en mascles indueix resistència a l'augment de pes induït per una dieta obesogènica. En el Capítol 2 hem demostrat que, en mascles, l'ablació de les neurones Nav1.8+ altera el control coordinat de la ingesta i les variacions de pes diàries, a més d'alterar la senyalització enteroendocrina i les oscil·lacions diàries de la microbiota intestinal en resposta a l'estat nutricional (dejuni/ingesta), i pertorbar l'homeòstasi del sistema immunitari intestinal. En el capítol 3, hem utilitzat un model de ratolí amb obesitat induïda per dieta per explorar els mecanismes pels quals Phascolarctobacterium faecium DSM 32890, una soca bacteriana intestinal aïllada d'humans metabòlicament sans, prevé l'obesitat modulant la ingesta. L'administració de P. faecium redueix la ingesta calòrica gràcies a la hipersecreció de l'hormona gastrointestinal saciant PYY. Independentment dels seus efectes anorexigènics, el bacteri exerceix els seus beneficis metabòlics estimulant el trànsit intestinal i reduint l'absorció intestinal de lípids, evitant l'acumulació de greix corporal. En conclusió, aquesta tesi doctoral proporciona evidència preclínica que contribueix a una comprensió més precisa de les vies neuroendocrines que comuniquen l'intestí i el cervell, i del paper que té la microbiota intestinal en la regulació de la ingesta i la despesa energètica. Destaquem la importància de les neurones sensorials aferents Nav1.8+ en la detecció d'estímuls intestinals per quimioreceptors per a regular l'equilibri energètic en ambdós sexes, que obri una nova línia d'investigació per a dissenyar ferramentes de neuromodulació de les neurones Nav1.8+ amb la finalitat de prevenir i tractar els trastorns metabòlics induïts per la dieta, de forma específica per a cada sexe. També destaquem que P. faecium és un bacteri candidat com a probiòtic de nova generació, ja que modula el sistema enteroendocrí de l'hoste i prevé l'obesitat en un model preclínic. En conjunt, aquests troballes proporcionen una base per al desenvolupament d'estratègies terapèutiques basades en l'intestí dirigides a combatre l'obesitat i comorbiditats associades., [EN] Obesity is a major global public health challenge that has reached epidemic proportions. Besides its profound impact on health and well-being, this metabolic disorder represents a significant economic burden to society. Our westernized environment where high-calorie foods are readily available, represents a major driver of the chronic imbalance between energy intake and energy expenditure that cause obesity. The limited effectiveness of behavioral interventions to manage long-term weight loss highlights the urgent need to develop more effective and minimally invasive approaches to prevent and treat obesity and its comorbidities. The development of gut-targeted therapeutic strategies to improve metabolic health requires a comprehensive understanding of the gut neuroendocrine signaling pathways that, in interaction with the gut microbiota, control feeding behavior to ultimately maintain energy balance. The aim of this thesis has been to gain insight into gut-brain interactions, including those mediated by endocrine, neural and gut microbial components, involved in the control of energy homeostasis, with a focus on obesogenic diet-related dysfunctions that increase susceptibility to develop obesity. In Chapters 1 and 2, we have investigated novel functions of sensory afferent neurons expressing the sodium channel Nav1.8 in the control of energy homeostasis, considering sex-specificities, by generating a mouse model lacking Nav1.8+ neurons through a diphtheria toxin ablation strategy. In Chapter 1, we show that Nav1.8+ neurons are required to control neural and endocrine pathways involved in energy homeostasis in a sex-specific manner. Specifically, ablation of Nav1.8+ neurons in females improves postprandial glucose regulation by enhancing glucagon-like peptide-1 enteroendocrine signaling and accelerating intestinal transit, whereas in males it induces resistance to weight gain in response to an obesogenic diet. To further explore the role of Nav1.8+ neurons in controlling food intake and pre- and post-prandial daily rhythms that influence metabolic phenotype, in Chapter 2 we show in males that ablation of Nav1.8+ sensory neurons impairs the coordinated control of food intake and body weight fluctuations throughout the day. The loss of these neurons also alters the physiological enteroendocrine signaling and daily gut microbiota oscillations in response to the nutritional status (fasting/refeeding cycles) and disrupts intestinal immune homeostasis. In Chapter 3, we used a diet-induced obese mouse model to investigate the mechanisms by which Phascolarctobacterium faecium DSM 32890, a gut bacterial strain isolated from metabolically healthy humans, prevents obesity by modulating food intake. We show that administration of P. faecium reduces caloric intake by promoting hypersecretion of a satiating gastrointestinal hormone, the peptide YY (PYY). Independently of its anorexigenic effects, the bacterium exerts its metabolic benefits via complementary mechanisms, specifically by stimulating intestinal transit and reducing intestinal lipid absorption, thereby preventing body fat accumulation. In conclusion, this doctoral thesis provides preclinical evidence for a better understanding of gut-to-brain neuroendocrine pathways and the role of gut microbiota in the regulation of food intake and energy expenditure. We highlight the importance of Nav1.8+ sensory afferent neurons in gut chemosensing for maintaining energy balance in both sexes, which prompts novel research lines and opportunities to design of sex-specific neuromodulation tools targeting Nav1.8+ neurons for prevention and treatment of diet-induced metabolic disorders. We also highlight that P. faecium is a promising next-generation probiotic candidate, as it modulates the host enteroendocrine system and prevents obesity in a preclinical model. Overall, our findings contribute to the development of gut-based therapeutic strategies to combat obesity and associated comorbidities., This study has been funded by the European Union 7th Framework Program through the MyNewGut project (Grant agreement No. 613979) and Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (MRP), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission – NextGenerationEU, through the CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+ (PTI-NEURO-AGING+)”. The grant of the Spanish Ministry of Science and Innovation (MCIN/AEI) to IATA-CSIC as Accredited Center of Excellence (CEX2021-001189-S/ MCIN/AEI/10.13039/501100011033) is acknowledged.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Intestinal group 1 innate lymphoid cells drive macrophage-induced inflammation and endocrine defects in obesity and promote insulinemia

  • Liébana-García, Rebeca
  • Olivares, Marta
  • Francés-Cuesta, Carlos
  • Rubio, Teresa
  • Rossini, Valerio
  • Quintás, Guillermo
  • Sanz, Yolanda
[EN] Hypercaloric diets overactivate the intestinal immune system and disrupt the microbiome and epithelial cell functions, impairing glucose metabolism. The origins of this inflammatory cascade are poorly characterized. We investigated the involvement of intestinal proinflammatory group 1 innate lymphoid cells (ILC1s) in obesity progression and metabolic disruption. In obese mice, we studied longitudinally the ILC1s response to the diet and ILC1s depletion to address its role in obesity. ILC1s are required for the expansion of pro-inflammatory macrophages and ILC2s. ILC1s depletion induced the ILC3-IL-22 pathway, increasing mucin production, antimicrobial peptides, and neuroendocrine cells. These changes were translated into higher gut hormones and reduced insulinemia and adiposity. ILC1s depletion was also associated with a bloom in Akkermansia muciniphila and decreases in Bilophila spp. Intestinal-ILC1s are upstream activators of inflammatory signals, connecting immunity with the microbiome, the enteroendocrine system, and the intestinal barrier in the control of glucose metabolism and adiposity., This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). An PFU contract to RL-G from the Spanish Ministry of Universities (PFU 18/02026) and a Marie Sklodowska Curie Actions (MSCA-IF) "MicroILCs" (GA: 8905454) contract to MO are acknowledged. The grant of Spanish Ministry of Science and Innovation (MCIN/AEI) of Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/ MCIN/AEI / 10.13039/501100011033) is also acknowledged.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Allium Derivate Propyl Propane Thiosulfinate Exerts Anti-Obesogenic Effects in a Murine Model of Diet-Induced Obesity

  • Liébana García, Rebeca
  • Olivares, Marta
  • Rodríguez Ruano, Sonia M.
  • Tolosa Enguís, Verónica
  • Chulia, Isabel
  • Gil Martínez, Lidia
  • Guillamón, Enrique
  • Baños, Alberto
  • Sanz Herranz, Yolanda
Allium species and their organosulfur-derived compounds could prevent obesity and metabolic dysfunction, as they exhibit immunomodulatory and antimicrobial properties. Here, we report the anti-obesogenic potential and dose-dependent effects (0.1 or 1 mg/kg/day) of propyl propane thiosulfinate (PTS) in a murine model of diet-induced obesity. The obesogenic diet increased body weight gain and adipocyte size, and boosted inflammatory marker (Cd11c) expression in the adipose tissue. Conversely, PTS prevented these effects in a dose-dependent manner. Moreover, the higher dose of PTS improved glucose and hepatic homeostasis, modulated lipid metabolism, and raised markers of the thermogenic capacity of brown adipose tissue. In the colon, the obesogenic diet reduced IL-22 levels and increased gut barrier function markers (Cldn3, Muc2, Reg3g, DefaA); however, the highest PTS dose normalized all of these markers to the levels of mice fed a standard diet. Gut microbiota analyses revealed no differences in diversity indexes and only minor taxonomic changes, such as an increase in butyrate producers, Intestimonas and Alistipes, and a decrease in Bifidobacterium in mice receiving the highest PTS dose. In summary, our study provides preclinical evidence for the protective effects of PTS against obesity, which if confirmed in humans, might provide a novel plant-based dietary product to counteract this condition., This study is supported by the Spanish Ministry of Science and Innovation (MICINN) (grants PID2020-119536RB-I00 and CIEN IDI-20170847). The FPU contract to R.L.-G. from Spanish Ministry of Universities (FPU 18/02026) and the contract Juan de la Cierva-Incorporación (IJCI-2017-32485) to MO are fully acknowledge., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tiny contributors to severe obesity inside the gut

  • Sanz Herranz, Yolanda
  • Olivares, Marta
YS is recipient of grants from the Spanish Ministry of Science and Innovation (MICINN) (PID2020-119536RB-I00 and PDC2021-121659-I00), Valencian Agency of Innovation (INNVA1/2021/32) and the European Commission H2020 Programme through the EarlyCause Project (grant agreement: 848158). MO is a beneficiary of a European Marie Skłodowska-Curie Action of H2020 (grant agreement: 890545)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intestinal group 1 innate lymphoid cells drive macrophage-induced inflammation and endocrine defects in obesity and promote insulinemia

  • Liébana García, Rebeca
  • Olivares, Marta
  • Francés Cuesta, Carlos
  • Rubio, Teresa
  • Rossini, Valerio
  • Quintas, Guillermo
  • Sanz Herranz, Yolanda
Hypercaloric diets overactivate the intestinal immune system and disrupt the microbiome and epithelial cell functions, impairing glucose metabolism. The origins of this inflammatory cascade are poorly characterized. We investigated the involvement of intestinal proinflammatory group 1 innate lymphoid cells (ILC1s) in obesity progression and metabolic disruption. In obese mice, we studied longitudinally the ILC1s response to the diet and ILC1s depletion to address its role in obesity. ILC1s are required for the expansion of pro-inflammatory macrophages and ILC2s. ILC1s depletion induced the ILC3-IL-22 pathway, increasing mucin production, antimicrobial peptides, and neuroendocrine cells. These changes were translated into higher gut hormones and reduced insulinemia and adiposity. ILC1s depletion was also associated with a bloom in Akkermansia muciniphila and decreases in Bilophila spp. Intestinal-ILC1s are upstream activators of inflammatory signals, connecting immunity with the microbiome, the enteroendocrine system, and the intestinal barrier in the control of glucose metabolism and adiposity., This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). An PFU contract to RL-G from the Spanish Ministry of Universities (PFU 18/02026) and a Marie Sklodowska Curie Actions (MSCA-IF) ”MicroILCs” (GA: 8905454) contract to MO are acknowledged. The grant of Spanish Ministry of Science and Innovation (MCIN/AEI) of Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIN/AEI /10.13039/501100011033) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fast profiling of primary, secondary, conjugated, and sulfated bile acids in human urine and murine feces samples

  • Ramos García, Victoria
  • Ten Doménech, Isabel
  • Vento, Máximo
  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • Sanz Herranz, Yolanda
  • Nobili, Angelica
  • Falcone, Marika
  • Di Stefano, Marina
  • Quintás, Guillermo
  • Kuligowski, Julia
Bile acids (BAs) are a complex class of metabolites that have been described as specific biomarkers of gut microbiota activity. The development of analytical methods allowing the quantification of an ample spectrum of BAs in different biological matrices is needed to enable a wider implementation of BAs as complementary measures in studies investigating the functional role of the gut microbiota. This work presents results from the validation of a targeted ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method for the determination of 28 BAs and six sulfated BAs, covering primary, secondary, and conjugated BAs. The analysis of 73 urine and 20 feces samples was used to test the applicability of the method. Concentrations of BAs in human urine and murine feces were reported, ranging from 0.5 to 50 nmol/g creatinine and from 0.012 to 332 nmol/g, respectively. Seventy-nine percent of BAs present in human urine samples corresponded to secondary conjugated BAs, while 69% of BAs present in murine feces corresponded to primary conjugated BAs. Glycocholic acid sulfate (GCA-S) was the most abundant BA in human urine samples, while taurolithocholic acid was the lowest concentrated compound detected. In murine feces, the most abundant BAs were α-murocholic, deoxycholic, dehydrocholic, and β-murocholic acids, while GCA-S was the lowest concentrated BA. The presented method is a non-invasive approach for the simultaneous assessment of BAs and sulfated BAs in urine and feces samples, and the results will serve as a knowledge base for future translational studies focusing on the role of the microbiota in health., This work was funded by the European Union’s Horizon 2020 Research and Innovation Programme through the Nutrishield project (https://nutrishield-project.eu/) [Grant Agreement No 818110] and the Carlos III Health Institute (Ministry of Science and Innovation, Spain) and co-funded by the European Union [grant numbers CD19/00176, and CPII21/00003], grant Despega IATA from IATA-CSIC, the Spanish Ministry of Science and Innovation [grant number PID2020-119536RB-I00], and MCIN/AEI/https://doi.org/10.13039/501100011033 and by ERDF A way of making Europe, by the “European Union” [grant number PID2021-125573OB-I00]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tracking microbiota fibre breakdown to treat NASH

  • Flor-Duro, Alejandra
  • Olivares, Marta
  • Sanz Herranz, Yolanda
This study has been supported by the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00). The Miguel Servet contract to M.O. is acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Ablation of Sensory Neurons Expressing the Nav1.8 Sodium Channel Improves Glucose Homeostasis and Amplifies the GLP-1 Signaling in Obese Female Mice

  • Romaní Pérez, Marina
  • Bullich Vilarrubias, Clara
  • López Almela, Inmaculada
  • Sanz Herranz, Yolanda
Sensory neurons expressing the sodium channel Nav1.8 contain a repertoire of receptors for nutrient, hormonal, and inflammatory ligands. However, their function in key regulators of energy homeostasis control is not well understood and is completely unexplored in females., This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (M.R.P.), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission – NextGenerationEU, through the “CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGING+” (PTI-NEURO-AGING+). The grant of the Spanish Ministry of Science and Innovation (MCIN/AEI) to IATA-CSIC as Accredited Center of Excellence (CEX2021-001189-S/ MCIN/AEI/10.13039/501100011033) is acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nav1.8-expressing neurons control daily oscillations of food intake, body weight and gut microbiota in mice

  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • López Almela, Inmaculada
  • Rubio, Teresa
  • García, Carlos J.
  • Tomás Barberán, Francisco
  • Sanz Herranz, Yolanda
Recent evidence suggests a role of sensory neurons expressing the sodium channel Nav1.8 on the energy homeostasis control. Using a murine diphtheria toxin ablation strategy and ad libitum and time-restricted feeding regimens of control or high-fat high-sugar diets, here we further explore the function of these neurons on food intake and on the regulation of gastrointestinal elements transmitting immune and nutrient sensing.The Nav1.8+ neuron ablation increases food intake in ad libitum and time-restricted feeding, and exacerbates daily body weight variations. Mice lacking Nav1.8+ neurons show impaired prandial regulation of gut hormone secretion and gut microbiota composition, and altered intestinal immunity.Our study demonstrates that Nav1.8+ neurons are required to control food intake and daily body weight changes, as well as to maintain physiological enteroendocrine and immune responses and the rhythmicity of the gut microbiota, which highlights the potential of Nav1.8+ neurons to restore energy balance in metabolic disorders., This study received funding from the European Union Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No. 797297 (MRP), the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00) and the European Commission – NextGenerationEU, through the CSIC Interdisciplinary Thematic Platform (PTI + ) NEURO-AGINGl+ (PTI-NEURO-AGING + )”. “Severo Ochoa” grant of National Agency for Research (AEI)- Ministry of Science and Innovation (Ref. CEX2021-001189-S) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Comparative Binding Study of Gliptins to Bacterial DPP4-like Enzymes for the Treatment of Type 2 Diabetes Mellitus (T2DM)

  • Carpio, Laureano E.
  • Olivares, Marta
  • Benítez-Páez, Alfonso
  • Serrano-Candelas, Eva
  • Barigye, Stephen J.
  • Sanz Herranz, Yolanda
  • Gozalbes, Rafael
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)., The role of the gut microbiota and its interplay with host metabolic health, particularly in the context of type 2 diabetes mellitus (T2DM) management, is garnering increasing attention. Dipeptidyl peptidase 4 (DPP4) inhibitors, commonly known as gliptins, constitute a class of drugs extensively used in T2DM treatment. However, their potential interactions with gut microbiota remain poorly understood. In this study, we employed computational methodologies to investigate the binding affinities of various gliptins to DPP4-like homologs produced by intestinal bacteria. The 3D structures of DPP4 homologs from gut microbiota species, including Segatella copri, Phocaeicola vulgatus, Bacteroides uniformis, Parabacteroides merdae, and Alistipes sp., were predicted using computational modeling techniques. Subsequently, molecular dynamics simulations were conducted for 200 ns to ensure the stability of the predicted structures. Stable structures were then utilized to predict the binding interactions with known gliptins through molecular docking algorithms. Our results revealed binding similarities of gliptins toward bacterial DPP4 homologs compared to human DPP4. Specifically, certain gliptins exhibited similar binding scores to bacterial DPP4 homologs as they did with human DPP4, suggesting a potential interaction of these drugs with gut microbiota. These findings could help in understanding the interplay between gliptins and gut microbiota DPP4 homologs, considering the intricate relationship between the host metabolism and microbial communities in the gut., This research was funded through a fellowship for researcher training contracts in companies (INNODOCTO, reference INNTAL32/19/002, INNTA3/2021/16, and INNTA3/2022/20) from the Valencian Agency for Innovation (AVI). This study was also funded by the grant PID2020-119536RB-I00 from the Spanish Ministry of Science, Innovation and Universities (MCIU) and grant APOTIP/2021/035 from Generalitat Valenciana. The authors also acknowledge the award of the Spanish Government MCIU/AEI to the IATA-CSIC as Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/MCIU/AEI/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacteroides uniformis CECT 7771 requires adaptive immunity to improve glucose tolerance but not to prevent body weight gain in diet-induced obese mice

  • Romaní Pérez, Marina
  • López Almela, Inmaculada
  • Bullich Vilarrubias, Clara
  • Evtoski, Zoran
  • Benítez-Páez, Alfonso
  • Sanz Herranz, Yolanda
Background: The metabolic disturbances of obesity can be mitigated by strategies modulating the gut microbiota. In this study, we sought to identify whether innate or adaptive immunity mediates the beneficial metabolic effects of the human intestinal bacterium Bacteroides uniformis CECT 7771 in obesity. Methods: We evaluated the effects of orally administered B. uniformis on energy homeostasis, intestinal immunity, hormone levels, and gut microbiota in wild-type and Rag1-deficient mice with diet-induced obesity. We also assessed whether B. uniformis needed to be viable to exert its beneficial effects in obesity and to directly induce immunoregulatory effects. Results: The administration of B. uniformis to obese mice improved glucose tolerance and insulin secretion, restored the caloric intake suppression after an oral glucose challenge, and reduced hyperglycemia. The pre- and post-prandial glucose-related benefits were associated with restoration of the anti-inflammatory tone mediated by type 2 macrophages and regulatory T cells (Tregs) in the lamina propria of the small intestine. Contrastingly, B. uniformis administration failed to improve glucose tolerance in obese Rag1-/- mice, but prevented the increased body weight gain and adiposity. Overall, the beneficial effects seemed to be independent of enteroendocrine effects and of major changes in gut microbiota composition. B. uniformis directly induced Tregs generation from naïve CD4+ T cells in vitro and was not required to be viable to improve glucose homeostasis but its viability was necessary to prevent body weight gain in diet-induced obese wild-type mice. Conclusions: Here we demonstrate that B. uniformis modulates the energy homeostasis in diet-induced obese mice through different mechanisms. The bacterium improves oral glucose tolerance by adaptive immunity-dependent mechanisms that do not require cell viability and prevents body weight gain by adaptive immunity-independent mechanisms which require cell viability., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This study received funding from the European Union 7th Framework Program through the MyNewGut project (Grant agreement No. 613979) and from the Spanish Ministry of Science and Innovation (grant PID2020-119536RB-I00). The FPI contract of I.L.-A. from the Ministry of Science and Innovation (Spain) and the contract of C. B-V for promotion of youth employment in R+D+I from Ministry of Science and Innovation (Spain) are fully acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The gut microbiota and diabetes: research, translation, and clinical applications - 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Niess, Jan Hendrik
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum ‘The microbiome and diabetes: research, translation and clinical applications’, including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). MB is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). SD is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. JHN is supported by the Swiss National Science Foundation (SNSF) grant 310030_219210. MN is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). YS is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (ref. CEX2021- 001189-S/10.13039/501100011033). VT is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX 2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut microbiota DPP4-like enzymes are increased in type-2 diabetes and contribute to incretin inactivation

  • Olivares, Marta
  • Hernández Calderón, Paula
  • Cárdenas Brito, Sonia
  • Liébana García, Rebeca
  • Sanz Herranz, Yolanda
  • Benítez-Páez, Alfonso
Background:The gut microbiota controls broad aspects of human metabolism and feeding behavior, but the basis for this control remains largely unclear. Given the key role of human dipeptidyl peptidase 4 (DPP4) in host metabolism, we investigate whether microbiota DPP4-like counterparts perform the same function. Results: We identify novel functional homologs of human DPP4 in several bacterial species inhabiting the human gut, and specific associations between Parabacteroides and Porphyromonas DPP4-like genes and type 2 diabetes (T2D). We also find that the DPP4-like enzyme from the gut symbiont Parabacteroides merdae mimics the proteolytic activity of the human enzyme on peptide YY, neuropeptide Y, gastric inhibitory polypeptide (GIP), and glucagon-like peptide 1 (GLP-1) hormones in vitro. Importantly, administration of E. coli overexpressing the P. merdae DPP4-like enzyme to lipopolysaccharide-treated mice with impaired gut barrier function reduces active GIP and GLP-1 levels, which is attributed to increased DPP4 activity in the portal circulation and the cecal content. Finally, we observe that linagliptin, saxagliptin, sitagliptin, and vildagliptin, antidiabetic drugs with DPP4 inhibitory activity, differentially inhibit the activity of the DPP4-like enzyme from P. merdae. Conclusions: Our findings confirm that proteolytic enzymes produced by the gut microbiota are likely to contribute to the glucose metabolic dysfunction that underlies T2D by inactivating incretins, which might inspire the development of improved antidiabetic therapies., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. The authors acknowledge the following funding bodies that provided support for this study: European Commission 7th Framework Program through the MyNewGut project (Grant agreement No. 613979) and the Spanish Ministry of Science and Innovation (MICINN) (grant PID2020-119536RB-I00) to YS; Institute of Health Carlos III (ISCIII) via CP19/00132 grant to AB-P with funds from the European Social Fund (ESF/FSE), CIPF Predoctoral Training Fellowships 2022 funded by JANSSEN-CILAG—supporting the contract of PH-C, CIPF core funding for the contract of SC-B; Early Career Grant from the Society for Endocrinology award to MO. Spanish Government MCIN/AEI for the Center of Excellence Accreditation Severo Ochoa (CEX2021-001189-S/ MCIN/AEI / https://doi.org/10.13039/501100011033)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Obesity and the gut microbiota: implications of neuroendocrine and immune signaling

  • Romaní Pérez, Marina
  • Líebana García, Rebeca
  • Flor Duro, Alejandra
  • Bonillo Jiménez, Daniel
  • Bullich Vilarrubias, Clara
  • Olivares, Marta
  • Sanz Herranz, Yolanda
Obesity is a major health challenge due to its high prevalence and associated comorbidities. The excessive intake of a diet rich in fat and sugars leads to a persistent imbalance between energy intake and energy expenditure, which increases adiposity. Here, we provide an update on relevant diet-microbe-host interactions contributing to or protecting from obesity. In particular, we focus on how unhealthy diets shape the gut microbiota and thus impact crucial intestinal neuroendocrine and immune system functions. We describe how these interactions promote dysfunction in gut-to-brain neuroendocrine pathways involved in food intake control and postprandial metabolism and elevate the intestinal proinflammatory tone, promoting obesity and metabolic complications. In addition, we provide examples of how this knowledge may inspire microbiome-based interventions, such as fecal microbiota transplants, probiotics, and biotherapeutics, to effectively combat obesity-related disorders. We also discuss the current limitations and gaps in knowledge of gut microbiota research in obesity., This study has been funded by the Spanish Ministry of Science and Innovation (Grant PID2020-119536RB-I00), the European Commission – NextGeneration EU, through the CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+. “(PTI-NEURO-AGING+)” and the “Severo Ochoa” grant of National Agency for Research (AEI)- Spanish Ministry of Science and Innovation (Ref. CEX2021-001189-S). The FPI contract to D. Bonillo from MICIN is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Hendrik Niess, Jan
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum “The Microbiome and Diabetes: Research, Translation and Clinical Applications,” including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). M.B. is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). S.D. is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. J.H.N. is supported by Swiss National Science Foundation (SNSF) grant 310030_219210. M.N. is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). Y.S. is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S/10.13039/501100011033). V.T. is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum

  • Byndloss, Mariana
  • Devkota, Suzanne
  • Duca, Frank
  • Niess, Jan Hendrik
  • Nieuwdorp, Max
  • Orho-Melander, Marju
  • Sanz Herranz, Yolanda
  • Tremaroli, Valentina
  • Zhao, Liping
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal., The 2023 Diabetes, Diabetes Care, and Diabetologia expert forum “The Microbiome and Diabetes: Research, Translation and Clinical Applications,” including a subsequent symposium presented on this topic and the preparation of this article, was supported by a grant from the Novo Nordisk Foundation (NNF23SA0085453). M.B. is a Howard Hughes Medical Institute Freeman Hrabowski Scholar and is supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) grant NIDDK R01DK131104, the Pew Charitable Trusts (2022-A-19568), and the Burroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease (022792). S.D. is supported by NIDDK grants NIDDK R01DK123446 and 1DP1 DK130687. J.H.N. is supported by Swiss National Science Foundation (SNSF) grant 310030_219210. M.N. is supported by a personal ZONMW-VICI grant 2020 (09150182010020) and a DFN-DON grant 2020 (2020.10.002). Y.S. is supported by grants from the Spanish Ministry of Science, Innovation and Universities MICIU/AEI (PID2020-119536RB-I00) and Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S/10.13039/501100011033). V.T. is a co-principal investigator of a research project funded by the European Union’s Innovative Medicines Initiative (IMI grant 875534)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Gut commensal Phascolarctobacterium faecium retunes innate immunity to mitigate obesity and metabolic disease in mice

  • Liébana García, Rebeca
  • López Almela, Inmaculada
  • Olivares, Marta
  • Romaní Pérez, Marina
  • Manghi, Paolo
  • Torres Mayo, Alba
  • Tolosa Enguís, Verónica
  • Flor Duro, Alejandra
  • Bullich Vilarrubias, Clara
  • Rubio, Teresa
  • Rossini, Valerio
  • Segata, Nicola
  • Sanz, Yolanda
The gut microbiota may protect against obesity and chronic metabolic conditions by regulating the immune response to dietary triggers. Yet the specific bacteria that control the overactivation of the immune system in obesity and their mode of action remain largely unknown. Here we surveyed 7,569 human metagenomes and observed an association between the gut symbiont Phascolarctobacterium faecium and non-obese adults regardless of nationality, sex or age. In a mouse model of diet-induced obesity, we confirmed the specificity of P. faecium DSM 32890 anti-obesogenic properties compared with other species of the same genus. P. faecium reversed the inflammatory phenotype associated with obesity. Specifically, P. faecium promoted polarization of alternatively activated macrophages (M2), which reversed the obesity-induced increase in gut-resident type 1 innate lymphoid cells. This resulted in mitigation of glucose intolerance, adiposity and body weight gain irrespective of treatment with live or pasteurized bacteria. The metabolic benefits were independent of the adaptive immune system, but they were abolished by an inhibitor of M2 polarization in mice. P. faecium directly promoted M2-macrophage polarization through TLR2 signalling and these effects seemed to be independent of gut microbiota changes. Overall, we identify a previously undescribed gut commensal bacterium that could help mitigate obesity and metabolic comorbidities by retuning the innate immune response to hypercaloric diets., This study was funded by the European Union 7th Framework Program through the MyNewGut project (Grant Agreement No. 613979) and the Spanish Ministry of Science, Innovation and Universities (MCIU; grant PID2020-119536RB-I00). The FPU and FPI grant contracts from the MCIU to R.L.-G. (FPU18/02026) and I.L.-A. (BES-2015-073930) and a Marie Sklodowska-Curie Actions (MSCA-IF) contract to M.O. (‘MicroILCs’, GA: 8905454) and M.R.-P. (‘miVaO’, GA: 797297) are acknowledged. The grant of accreditation as a Severo Ochoa Center of Excellence from MCIN/AEI (CEX2021- 001189-S/ MCIN/AEI / 10.13039/501100011033) is also acknowledged., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S), Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Safety and Tolerability of the Gut Bacterium Phascolarctobacterium faecium DSM 32890

  • Tamayo, María
  • Tolosa-Enguis, Veronica
  • Alabadi, Blanca
  • Olivares, Marta
  • Romera, Sergio
  • Orti, Leticia
  • Terrado, Elisabet
  • Flor Duro, Alejandra
  • Morillas, Carlos
  • Codoñer, Pilar
  • Real, José T.
  • Sanz Herranz, Yolanda
This article belongs to the Section Prebiotics, Probiotics and Postbiotics, [Background/Objectives] The prevalence of the commensal gut bacterium species, Phascolarctobacterium faecium, has been associated with normal weight in humans. Preclinical evidence suggests that the strain P. faecium DSM 32890 exerts beneficial effects on metabolic and immune function in diet-induced obesity. Herein, we aimed to evaluate the safety and tolerability of this strain in a preclinical study and a pilot interventional trial in humans., [Methods] A repeated-dose oral toxicity study of 28 days was performed in Wistar rats (male and female), during which adverse signs and clinical outcomes were assessed, along with histological, hematologic, biochemical, and immune markers. Subsequently, a pilot human intervention trial was conducted, including 20 participants (11 overweight and 9 normal weight) who received P. faecium DSM 32890 daily for 15 days. Body composition, dietary intake, physical activity, clinical data, perceived health, gastrointestinal symptoms, and blood analyses were assessed to determine tolerability and identify potential adverse effects., [Results] In rats, the administration of the bacterium did not cause behavioral, physiological, histologic, immune, or biochemical alterations. In humans, there was no evidence of adverse effects on general health, hematological and biochemical profiles, bowel habits, or gastrointestinal symptoms. Overweight participants experienced reductions in flatulence and nausea after the intervention., [Conclusions] The consumption of P. faecium DSM 32890 did not raise safety concerns and was well tolerated in rats and humans. The findings represent a step forward in the path toward future, longer-term studies to explore the potential efficacy., This research was funded by Ministry of Science, Innovation and Universities (MCIU, 610 grants: PID2020-119536RB-I00 and PID2023-150693OB-I00.) and by Agencia Valenciana de la Innovación (AVI/IVACE) de la Generalitat Valenciana (Ref INNVA1/2020/25). The accreditation as a Severo Ochoa 611 Center of Excellence to IATA-CSIC from MCIN/AEI (CEX2021-001189-S/MCIN/AEI/612 10.13039/501100011033) is acknowledged., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phascolarctobacterium faecium reduces food intake via PYY signaling, contributing to the mitigation of body weight gain in diet-induced obese mice

  • Bullich Vilarrubias, Clara
  • Romaní Pérez, Marina
  • López-Almela, Inmaculada
  • Pomares Díaz, Carlos
  • Basili Franzin, Silvia
  • Esposito, Giuseppe
  • Benítez-Páez, Alfonso
  • Tolosa Enguís, Verónica
  • Sanz Herranz, Yolanda
Excess energy intake contributes to adiposity in obesity. We investigated whether the human intestinal bacterium Phascolarctobacterium faecium could prevent obesity via enteroendocrine pathways in a mouse model of diet-induced obesity (DIO). Daily administration of P. faecium (2 × 109 cells/mouse) reduced food intake through the early overproduction of the satiety hormone peptide YY (PYY) compared to untreated DIO mice. Moreover, P. faecium increased the intestinal levels of branched-chain amino acids, which, in turn, stimulated PYY secretion in neuroendocrine cell cultures and also modified gut microbiota composition. A pair-feeding study demonstrated that the anorexigenic effect of P. faecium contributes to its effects in attenuating body weight gain in DIO mice, but that other mechanisms are also involved in its metabolic benefits. Specifically, P. faecium accelerated gut transit and serum lipid clearance, thereby limiting adiposity independently of food intake. This study identifies the mode of action of a human intestinal bacterium recently linked to obesity protection, providing valuable insights into host-microbe interactions governing body weight., This study has been funded by the European Union 7th Framework Program through MyNewGut project (Grant agreement No. 613979), the Spanish Ministry of Science, Innovation and Universities (MCIU; grants PID2020-119536RB-I00, PID2023-150693OB-I00) and the European Commission – NextGenerationEU, through CSIC Interdisciplinary Thematic Platform (PTI+) NEURO-AGINGl+. (PTI-NEURO-AGING+)”. (EU (European Union)), With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Relation Between Gut Microbiome and Inflammatory Interleukins in Psoriasis Patients Compared to Healthy Controls: An Observational Study

  • Schneller-Pavelescu, L.
  • Mora Martínez, Carlos
  • Sánchez-Pujol, M.J.
  • Sanz Herranz, Yolanda
  • Caparrós Cayuela, E.
  • Francés Guarinos, R.
  • Ramos Rincón, J.M.
  • Belinchón Romero, I.
The gut microbiota interacts with the immune system and plays an important role in many inflammatory diseases such as psoriasis, although the exact mechanisms in this disease are not yet well understood., This project was funded by a Grant from the 7th Call for Research Support of Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (Alicante Spain) (2020) (projects 2020-0348 and 2020-0289). The study by YS and CM is funded by a project (PID2020-119536RB-100) from the Spanish Ministry of Science, Innovation and Universities (MCIU) and the Spanish Research Agency (AEI)/MCIU to IATA as a Severo Ochoa Center of Excellence (Ref. CEX2021-001189-S)., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2021-001189-S)., Peer reviewed